Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase

D. Seto-Young, D. Avtanski, G. Parikh, P. Suwandhi, M. Strizhevsky, T. Araki, Z. Rosenwaks, L. Poretsky

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The effects of rosiglitazone or pioglitazone (thiazolidinediones, TZDs) on estrogen production and aromatase activity in human ovarian cells were examined. Human granulosa cells were incubated in the tissue culture medium supplemented with androstenedione or testosterone, with or without insulin, TZDs, or type 1 17-hydroxysteroid-dehydrogenase (17-HSD) inhibitor. Estrogen concentrations in the conditioned medium, aromatase mRNA and protein expression in the cells and androgen substrate binding to aromatase were measured. With androstenedione as substrate, rosiglitazone or pioglitazone inhibited estrone production by up to 22% (p<0.012) while type 1 17-HSD inhibitor enhanced this effect of rosiglitazone or pioglitazone by 37% (p<0.001) and by 67% (p<0.001), respectively. With testosterone as substrate, rosiglitazone or pioglitazone inhibited estradiol production by 32% (p<0.001). With 3H- testosterone as substrate, rosiglitazone or pioglitazone inhibited the 3H-tritiated water release by the cultured cells by 45% and 35%, respectively, thus directly demonstrating inhibition of aromatase. Rosiglitazone or pioglitazone, however, had no significant effect on aromatase mRNA or protein expression. Rosiglitazone or pioglitazone inhibited 125I- androstenedione and 125I-testosterone binding to aromatase by 38% (p<0.001). It was concluded that rosiglitazone or pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.

Original languageEnglish (US)
Pages (from-to)250-256
Number of pages7
JournalHormone and Metabolic Research
Volume43
Issue number4
DOIs
StatePublished - 2011

Fingerprint

rosiglitazone
pioglitazone
Aromatase
Granulosa Cells
Androgens
Estrogens
Testosterone
Androstenedione
Thiazolidinediones
Substrates
Tissue culture
Messenger RNA
Estrone
Conditioned Culture Medium
Human Activities

Keywords

  • aromatase
  • estrogens
  • insulin sensitivity
  • polycystic ovary syndrome
  • PPAR-
  • thiazolidinediones

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. / Seto-Young, D.; Avtanski, D.; Parikh, G.; Suwandhi, P.; Strizhevsky, M.; Araki, T.; Rosenwaks, Z.; Poretsky, L.

In: Hormone and Metabolic Research, Vol. 43, No. 4, 2011, p. 250-256.

Research output: Contribution to journalArticle

Seto-Young, D, Avtanski, D, Parikh, G, Suwandhi, P, Strizhevsky, M, Araki, T, Rosenwaks, Z & Poretsky, L 2011, 'Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase', Hormone and Metabolic Research, vol. 43, no. 4, pp. 250-256. https://doi.org/10.1055/s-0030-1270525
Seto-Young, D. ; Avtanski, D. ; Parikh, G. ; Suwandhi, P. ; Strizhevsky, M. ; Araki, T. ; Rosenwaks, Z. ; Poretsky, L. / Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. In: Hormone and Metabolic Research. 2011 ; Vol. 43, No. 4. pp. 250-256.
@article{d38187768d6d486194667907704d53a8,
title = "Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase",
abstract = "The effects of rosiglitazone or pioglitazone (thiazolidinediones, TZDs) on estrogen production and aromatase activity in human ovarian cells were examined. Human granulosa cells were incubated in the tissue culture medium supplemented with androstenedione or testosterone, with or without insulin, TZDs, or type 1 17-hydroxysteroid-dehydrogenase (17-HSD) inhibitor. Estrogen concentrations in the conditioned medium, aromatase mRNA and protein expression in the cells and androgen substrate binding to aromatase were measured. With androstenedione as substrate, rosiglitazone or pioglitazone inhibited estrone production by up to 22{\%} (p<0.012) while type 1 17-HSD inhibitor enhanced this effect of rosiglitazone or pioglitazone by 37{\%} (p<0.001) and by 67{\%} (p<0.001), respectively. With testosterone as substrate, rosiglitazone or pioglitazone inhibited estradiol production by 32{\%} (p<0.001). With 3H- testosterone as substrate, rosiglitazone or pioglitazone inhibited the 3H-tritiated water release by the cultured cells by 45{\%} and 35{\%}, respectively, thus directly demonstrating inhibition of aromatase. Rosiglitazone or pioglitazone, however, had no significant effect on aromatase mRNA or protein expression. Rosiglitazone or pioglitazone inhibited 125I- androstenedione and 125I-testosterone binding to aromatase by 38{\%} (p<0.001). It was concluded that rosiglitazone or pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.",
keywords = "aromatase, estrogens, insulin sensitivity, polycystic ovary syndrome, PPAR-, thiazolidinediones",
author = "D. Seto-Young and D. Avtanski and G. Parikh and P. Suwandhi and M. Strizhevsky and T. Araki and Z. Rosenwaks and L. Poretsky",
year = "2011",
doi = "10.1055/s-0030-1270525",
language = "English (US)",
volume = "43",
pages = "250--256",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase

AU - Seto-Young, D.

AU - Avtanski, D.

AU - Parikh, G.

AU - Suwandhi, P.

AU - Strizhevsky, M.

AU - Araki, T.

AU - Rosenwaks, Z.

AU - Poretsky, L.

PY - 2011

Y1 - 2011

N2 - The effects of rosiglitazone or pioglitazone (thiazolidinediones, TZDs) on estrogen production and aromatase activity in human ovarian cells were examined. Human granulosa cells were incubated in the tissue culture medium supplemented with androstenedione or testosterone, with or without insulin, TZDs, or type 1 17-hydroxysteroid-dehydrogenase (17-HSD) inhibitor. Estrogen concentrations in the conditioned medium, aromatase mRNA and protein expression in the cells and androgen substrate binding to aromatase were measured. With androstenedione as substrate, rosiglitazone or pioglitazone inhibited estrone production by up to 22% (p<0.012) while type 1 17-HSD inhibitor enhanced this effect of rosiglitazone or pioglitazone by 37% (p<0.001) and by 67% (p<0.001), respectively. With testosterone as substrate, rosiglitazone or pioglitazone inhibited estradiol production by 32% (p<0.001). With 3H- testosterone as substrate, rosiglitazone or pioglitazone inhibited the 3H-tritiated water release by the cultured cells by 45% and 35%, respectively, thus directly demonstrating inhibition of aromatase. Rosiglitazone or pioglitazone, however, had no significant effect on aromatase mRNA or protein expression. Rosiglitazone or pioglitazone inhibited 125I- androstenedione and 125I-testosterone binding to aromatase by 38% (p<0.001). It was concluded that rosiglitazone or pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.

AB - The effects of rosiglitazone or pioglitazone (thiazolidinediones, TZDs) on estrogen production and aromatase activity in human ovarian cells were examined. Human granulosa cells were incubated in the tissue culture medium supplemented with androstenedione or testosterone, with or without insulin, TZDs, or type 1 17-hydroxysteroid-dehydrogenase (17-HSD) inhibitor. Estrogen concentrations in the conditioned medium, aromatase mRNA and protein expression in the cells and androgen substrate binding to aromatase were measured. With androstenedione as substrate, rosiglitazone or pioglitazone inhibited estrone production by up to 22% (p<0.012) while type 1 17-HSD inhibitor enhanced this effect of rosiglitazone or pioglitazone by 37% (p<0.001) and by 67% (p<0.001), respectively. With testosterone as substrate, rosiglitazone or pioglitazone inhibited estradiol production by 32% (p<0.001). With 3H- testosterone as substrate, rosiglitazone or pioglitazone inhibited the 3H-tritiated water release by the cultured cells by 45% and 35%, respectively, thus directly demonstrating inhibition of aromatase. Rosiglitazone or pioglitazone, however, had no significant effect on aromatase mRNA or protein expression. Rosiglitazone or pioglitazone inhibited 125I- androstenedione and 125I-testosterone binding to aromatase by 38% (p<0.001). It was concluded that rosiglitazone or pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.

KW - aromatase

KW - estrogens

KW - insulin sensitivity

KW - polycystic ovary syndrome

KW - PPAR-

KW - thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=79953291240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953291240&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1270525

DO - 10.1055/s-0030-1270525

M3 - Article

C2 - 21321839

AN - SCOPUS:79953291240

VL - 43

SP - 250

EP - 256

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 4

ER -